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Abstract: I would like to welcome breast cancer research community to the ﬁ  rst editorial of our newest journal “Breast 
Cancer: Basic and Clinical Research”. In pursuit of breast cancer culprits, we have come a long way since the early 90’s 
when the ﬁ  rst breast cancer susceptibility gene BRCA1 was mapped and cloned. In the past few years, several new loci 
associated with the various degree of breast cancer risk have been identiﬁ  ed using “Candidate Gene Association Study 
(CGAS) and Genome-Wide Association Study (GWAS)” approaches. This editorial is meant to quickly glance over recent 
ﬁ  ndings of these population-based association studies.
Introduction
Breast cancer is one of the most terrifying diseases that human civilization has ever known. Legend 
has it that powerful queen Atossa of the ancient Babylon had breast cancer, and the speciﬁ  c mention of 
breast cancer can be found in “Hippocratic Corpus” written by Hippocrates and his peers dating back 
to fourth and ﬁ  fth centuries B.C. (Karpozilos and Pavlidis, 2004). Throughout our past and present 
civilization, we are reminded that several notable ﬁ  gures and ordinary citizens have suffered or are 
suffering from this dreadful disease. Although the life-time risk of developing breast cancer may vary 
in different geographic regions of the world, nobody is immune to developing breast cancer. In the 
United States of America and most western countries, the life-time risk of developing breast cancer in 
women is close to 1 in 8. The most intriguing question is- what determines this risk?
It is well known that early onset breast cancer tends to cluster in families and usually ﬁ  rst degree 
relatives of affected individuals have twofold higher risk of developing breast cancer (2001). This 
increased risk is independent of lifestyle and environmental factors, and thought to be due to genetic 
susceptibility of individuals to develop breast cancer (Lichtenstein et al. 2000). The early onset breast 
cancer, which tends to cluster in families, is also known as familial breast cancer. Overall, 20%–25% 
of familial breast cancer is attributed to high penetrance genes BRCA1, BRCA2, TP53, and PTEN 
(Easton, 1999).
The high penetrance genes were identiﬁ  ed using family-based linkage studies. These studies also 
identiﬁ  ed additional breast cancer susceptibility genes. In all, these family-based linkage studies were 
instrumental in identifying ten important genes- BRCA1, BRCA2, TP53, PTEN, CHEK2, ATM, NBS1, 
RAD50, BRIP1, and PALB2 for inherited breast cancer (Walsh and King, 2007). These ten genes, which 
are critical for genome integrity account for roughly 50% of familial breast cancer (Walsh and King, 
2007). Despite intense efforts, linkage studies have failed to identify additional breast cancer suscepti-
bility genes for familial breast cancer.
The late onset breast cancer, which is primarily sporadic in nature, is by far the most prevalent. 
In sporadic breast cancer, “the 10 genes for inherited breast cancer” have very minimal role. Hence, 
the 50% of the familial or early onset cases and majority of late onset cases of breast cancer must 
involve low to medium penetrance genes. The linkage studies lack the power to detect alleles respon-
sible for low to moderate risk of developing breast cancer. Such alleles are now being identiﬁ  ed using 
population-based gene-association studies. These studies take advantage of thousands of known 
single-nucleotide polymorphisms (SNPs) present in the human genome. The earlier studies focused 
on candidate gene approach and looked for SNPs in limited number of genes and their possible 2
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association with breast cancer. More recent 
studies known as Genome-Wide Association 
Studies (GWASs) are taking advantage of unbi-
ased scan of the whole genome for SNPs associ-
ated with breast cancer risk.
The Usual Suspects: Candidate 
Gene Association Studies
Several breast cancer research groups have studied 
the association of breast cancer risk with common 
variants (SNPs) of candidate genes. More compre-
hensive CGASs have been carried out by SEARCH 
breast cancer study group and the “Breast Cancer 
Association Consortium” (BCAC). Results of 
CGASs have been mixed and very confusing. 
Some of the association studies may not be directly 
comparable because they used different population 
groups, while in other studies, the sample size may 
not be sufﬁ  ciently large enough.
Starting with HER-2, in some studies a com-
mon variant HER-2 V655I was reported to be 
associated with breast cancer (Xie et al. 2000), 
however other studies found no such association 
(Benusiglio et al. 2006; Einarsdottir et al. 2006). 
Human CYP19 gene, which encodes aromatase 
cytochrome P450 is another plausible candidate 
gene where some studies have suggested asso-
ciation of common variants with signiﬁ  cant breast 
cancer risk (Haiman et al. 2003; Ralph et al. 
2007), while other studies suggested no associa-
tion of any SNPs in CYP19 with breast cancer 
risk (Healey et al. 2000). Recently, Ralph et al. 
suggested possible age-speciﬁ  c association of 
certain SNPs present in genes encoding steroid 
hormone pathway (Ralph et al. 2007). Speciﬁ  cally, 
it was reported that cytosine/cytosine homozy-
gous genotype of cytochrome P450 XIB2 
(CYP11B2) was associated with reduced breast 
cancer risk at younger age, but increased risk at 
older age (Ralph et al. 2007), and homozygous 
cytosine-guanine (CG/CG) genotype of uridine 
phosphorylase glycosyltransferase 1A7 (UGT1A7) 
was associated with increased breast cancer risk 
at younger ages but decreased risk at older ages 
(Ralph et al. 2007).
By analyzing 4,474 breast cancer cases and 
4,560 controls from SEARCH collection (United 
Kingdom), Baynes et al. reported that in contrast 
to rare variants, the common variants in the ATM, 
BRCA1, BRCA2, CHEK2 and TP53 are unlikely to 
increase the breast cancer risk (Baynes et al. 2007). 
A study be Onay et al. also concluded that 19 
individual commonly occurring SNPs associated 
with 18 key cancer genes XPD, PTEN, GADD45, 
p27, ESR1, CYP17, GSTM3, MTHFR, IL1a, IL10, 
IL13, TNFa, G-CSF, CCND1, COMT, BARD1, 
GSTP1 and MMP1 did not contribute to breast 
cancer risk (Onay et al. 2006). A very recent BCAC 
study also did not ﬁ  nd an association of MDM2 
SNP309 and TP53 R72P SNP with breast cancer 
risk (Schmidt et al. 2007).
On the other hand, common variants of few 
genes, which were suspected to play a role in breast 
cancer did turned out to have weak association with 
breast cancer risk. For example, BCAC reported 
that common coding variants CASP8 D302H in 
the gene encoding Caspase 8, and TGFB1 L10P in 
the gene encoding transforming growth factor-β 
(TGFβ), in one allele (heterozygote) were associ-
ated with signiﬁ  cant risk to invasive breast cancer 
(Cox et al. 2007). In an earlier study, CASP8 
D302H variant was reported to be associated with 
reduced breast cancer risk in a dose-dependent 
manner; it provided better protection against breast 
cancer in the homozygous condition (MacPherson 
et al. 2004).
BCAC also analyzed data from 12 studies for 
16 SNPs in various candidate genes and concluded 
that only 5 SNPS (CASP8 D302H, IGFBP3-202 
c   a, PGRV660L, SOD2 V16A, and TGFB1 
L10P) were associated with breast cancer, but the 
statistical signiﬁ  cance of the association was only 
borderline (Breast Cancer Association, 2006). The 
remaining 11 SNPs in other candidate genes 
showed no signiﬁ  cant association with breast 
cancer risk (Breast Cancer Association, 2006). 
Another recent study (SEARCH investigators), 
which analyzed association between common 
variants found in 120 candidate genes and breast 
cancer concluded that a proportion of SNPs in 
candidate genes in the cell-cycle control pathway, 
genes involved in steroid hormone metabolism 
and signaling were weakly associated with breast 
cancer risk but large sample-sizes from multicen-
tre collaboration is needed to identify SNPs that 
are associated with deﬁ  nitive breast cancer risk 
(Pharoah et al. 2007). Some borderline signiﬁ  -
cance of SNPs in few selected antioxidant defense 
genes (for example CAT g27168a, TXN t2715c, 
TXNRD2 A66S and TXNRD2 g23524a) and epi-
genetic genes (for example DNMT3b-c31721t) 
with breast cancer risk has been reported but these 
observations need to be confirmed in larger 3
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epidemiological studies (Cebrian et al. 2006a; 
Cebrian et al. 2006b).
Not so Usual Suspects: Genome-
Wide Association Studies
As discussed above, the candidate gene approach 
studies to identify breast cancer risk has not been 
very successful. With the advent of rapid SNP 
screening technologies and completion of “Hap 
Map”, it is now possible to rapidly scan the genome 
of several thousand individuals to ﬁ  nd association 
of SNPs with a particular disease. Recently, four 
such GWASs have been conducted to identify 
novel breast cancer susceptibility loci (Easton et al. 
2007; Hunter et al. 2007; Murabito et al. 2007; 
Stacey et al. 2007).
Stacey et al. genotyped 4,554 breast cancer 
patients and 17,577 controls using the Illumina 
Hap300 platform and reported that individuals of 
European descent with homozygous allele A of 
rs13387042 SNP on chromosome 2q35 have an 
estimated 1.44 fold higher risk of estrogen receptor-
positive (ER-positive) breast cancer compared to 
noncarriers, while homozygous allele T of 
rs3803662 on chromosome 16q12 was associated 
with 1.64 fold risk of ER-positive breast cancer 
(Stacey et al. 2007). Among other ethnicities, both 
variants were only marginally signiﬁ  cant; in fact 
T-rs3803662 allele was protective in African 
Americans (Stacey et al. 2007). Functional sig-
niﬁ  cance of both these SNPs is not clear, although 
rs3803662 is near the 5’ end of TNRC9, a gene 
implicated in bone metastasis of breast cancer cells. 
Remarkably, signiﬁ  cant breast cancer association 
of rs3803662 SNP near the 5’ end of TNRC9 was 
also reported in an independent study (Easton et al. 
2007).
The discovery of association of SNPs in intron 
2 of FGFR2, which encode ﬁ  broblast growth fac-
tor receptor 2, with breast cancer risk was also 
reported in two independent GWASs (Easton et al. 
2007; Hunter et al. 2007). In the ﬁ  rst study, which 
also tagged rs3803662, GWAS was carried out 
using a two-stage analysis of 4,398 breast cancer 
cases and 4,316 controls. At second stage, authors 
found signiﬁ  cant association of 1,792 SNPs with 
breast cancer risk, but chose to study 30 SNPs with 
highest level of signiﬁ  cance for subsequent con-
ﬁ  rmation in 21,860 cases and 22,578 controls 
chosen from 22 studies (Easton et al. 2007). The 
following SNPs showed the most signiﬁ  cant and 
consistent evidence of association- rs2981582 
(FGFR2), and rs12443621, rs8051542 and 
rs3803662 (TNRC9), rs889312 (MAP3K1), 
rs13281615 (8q) and rs3817198 (LSP1) (Easton 
et al. 2007). Although FGFR, TNRC9, MAP3K1 
and LSP1 are plausible breast cancer culprits, the 
functional signiﬁ  cance of SNPs in these genes 
remain unclear at this point (Easton et al. 2007).
In the second GWAS, Hunter et al. genotyped 
528,173 SNPs in 1,145 postmenopausal women of 
European descent with invasive breast cancer and 
1,142 controls (Hunter et al. 2007). The GWAS 
identified four SNPs (rs1219648, rs2420946, 
rs11200014 and rs2981579) in intron 2 of FGFR2, 
which showed signiﬁ  cant association with breast 
cancer (Hunter et al. 2007). The association was 
conﬁ  rmed using three additional studies using 
1,776 cases and 2,072 controls (Hunter et al. 2007). 
Again, although FGFR2 is a plausible breast cancer 
gene, the functional signiﬁ  cance of these common 
variants in FGFR2 loci is not clear.
Another GWAS was conducted by Murabito et al. 
using study subjects from NHLBI’s Framingham 
Heart Study (Murabito et al. 2007). The study 
involved 1,335 participants, including 58 women 
with breast cancer and 59 men with prostate cancer 
(Murabito et al. 2007). Possibly, because of limited 
size of the population, authors did not ﬁ  nd sig-
niﬁ  cant association of any SNP with breast or 
prostate cancer risk. Although in the same study, 
using candidate gene approach, authors reported 
signiﬁ  cant association of two SNPs (rs9325782 
and rs2410373) in MSRI gene with prostate cancer, 
and three SNPs (rs905883, rs7564590 and 
rs7558615) in ERBB4 with breast cancer (Murabito 
et al. 2007).
Conclusion: Devil is Hiding 
in the Genome
With the rapid advent of genotyping technologies, 
we have entered an exciting era of genome-based 
discoveries for human diseases. CGAS and GWAS 
clearly have the power to identify common variants 
that are associated with low susceptibility loci for 
a particular disease. At present, due to continued 
drop in genotyping costs, GWAS appears to be a 
better approach than CGAS. However, a great 
degree of caution is needed in the correct interpre-
tation of such studies. There are several issues 
which need to be addressed in each GWAS; the 
caveats range from sample size to genotyping 4
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quality controls to successful replication of results. 
Several of these points are discussed in NCI-
NHGRI (National Cancer Institute-National 
Human Genome Research Institute) working group 
recommendations on replicating GWAS results 
(Chanock et al. 2007).
The next legitimate question is- what is the 
overall risk of a particular disease associated with 
these so called common variants? Although statis-
tically signiﬁ  cant, the effect of individual SNP is 
generally very small in terms of increasing breast 
cancer risk. Such risk is usually close to 1.2 to 1.5. 
However, the overall effect of combinations of 
SNPs on breast cancer risk may be substantial. This 
overall effect, which is also termed as polygenic 
effect (of SNPs) may be additive or synergistic and 
may account for most of the genetic risk associated 
with developing breast cancer. Although, only a 
handful of these common variants have been iden-
tiﬁ  ed so far, the presumption is that there are many 
more of these, and they may genetically interact.
For now, the breast cancer community will wait 
for the identiﬁ  cation of all of the common variants 
in the genome, which would be associated with 
breast cancer, and then all of us- clinical and basic 
scientists, and other stake holders will debate what 
is in the best interest of naïve general public. 
Should we prepare for the genetic counseling of 
would be breast cancer patients even though the 
overall risk factor may still be below 1.5 to 2.0? 
In summary, each GWAS starts with an assumption 
that the evildoers are in the genome and that they 
most probably conspire together to increase the 
risk of developing a particular disease such as 
breast cancer. On an optimistic note, the gene hunt-
ers or SNP hunters to be more accurate, are busy 
hunting these evildoers, wherever they may be- in 
the introns, exons or the regulatory regions in the 
genome.
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